Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AFM24 + SNK01|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AFM24||AFM-24|AFM 24||EGFR Antibody 39||AFM24 is a bispecific antibody against EGFR and CD16A, which may result in an anti-tumor immune response, specifically, natural killer cells targeting tumor cells that express Egfr (J Clin Oncol 35, 2017 (suppl; abstr e14001)).|
|SNK01||SNK-01|SNK 01||SNK01 is a modified autologous natural killer cell therapy, which potentially increases cytotoxicity against tumor cells (J. of Clin. Onc. 2020 38:15_suppl, e15024).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05099549||Phase Ib/II||AFM24 + SNK01||Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers||Recruiting||USA||0|